Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms

Vascular and Endovascular Surgery

Volumn 44, Issue 2, 2010, Pages 116-122

  Schweitzer, Morris ^a   Mitmaker, Benjamin ^a   Obrand, Daniel ^a   Sheiner, Nathan ^a   Abraham, Cherrie ^a   Dostanic, Stevan ^b   Meilleur, Melissa ^b   Sugahara, Tomoko ^b   Chalifour, Lorraine E ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Abdominal aortic aneurysm; Atorvastatin; Matrix metalloproteinase; TGF signaling

Indexed keywords

ATORVASTATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; SMAD2 PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA;

ABDOMINAL AORTA ANEURYSM; AGED; ANEURYSM SURGERY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

AGED; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; DOWN-REGULATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MATRIX METALLOPROTEINASES; PHOSPHORYLATION; PYRROLES; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 76049120774     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574409348352     Document Type: Article

References (35)

1. Thompson RW, Geraghty PJ, Lee JK Abdominal aortic aneurysm: basic mechanisms and clinical implications. Curr Probl Surg. 2002 ; 39 (2). 110-230.
2. Golledge J., Abrokwah J., Shenoy KN, Armour RH Morphology of ruptured abdominal aneurysms. Eur J Vasc Endovasc Surg. 1999 ; 18 (2). 96-104.
3. Raffetto JD, Khalil RA Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008 ; 75 (2). 346-359.
4. George SJ Tissue inhibitors of metalloproteinase and metalloproteinases in atherosclerosis. Curr Opin Lipid. 1998 ; 9 (5). L413 - L423.
5. Longo GM, Xiong W., Grenier TG, Zhao Y., Fiotti N., Baxter BT Matrix metalloproteinase 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2003 ; 110 (5). 625-632.
6. Pyo R., Lee JK, Shipley M., et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000 ; 105 (11). 1641-1649.
7. Silence J., Lupu F., Collen D., Lijnen HR Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001 ; 21 (9). 1440-1447.
8. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemia. Drugs. 1997 ; 53 (5). 828-847. (Pubitemid 27195013)
9. Kalyanasundaram A., Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg. 2006 ; 43 (1). 117-124.
10. Kertai MD, Boersma E., Westerhout CM, et al. Association between long-statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med. 2004 ; 116 (2). 96-103.
11. Leurs JJ, Visser P., Laheij RJ, Buth J., Harrris PL, Blankensteijn JD Statin use is associated with reduced all-cause mortality after endovascular abdominal aortic aneurysm repair. Vascular. 2006 ; 14 (1). 1-8.
12. Sukjija R., Aronwo WS, Sandhu R., Kakar P., Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006 ; 97 (2). 279-280.
13. Schouten O., van Laanen JH, Boersma E., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Endovasc Surg. 2006 ; 32 (1). 21-26.
14. Crisby M., Nordin-Fredriksson G., Shah PK, Yano J., Zhu J., Nilsson J. Pravastatin treatment increased collagen content and decreases lipid content, inflammation, metalloproteinase and cell death in human carotid plaques. Circulation. 2001 ; 103 (7). 926-933.
15. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Artheroscler Thromb Vasc Biol. 1998 ; 18 (11). 1671-1678.
16. Ganne F., Vasse M., Beaudeux JL, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP9 secretion by peripheral blood monocytes-a possible protective mechanism again atherothrombosis. Thromb Haemost. 2000 ; 84 (4). 680-688.
17. Suzuki H., Kobayashi H., Sata F., Yonemitsu Y., Nakashima Y., Sueishi K. Plaquestabilizing effects of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb. 2003 ; 10 (2). 109-116.
18. Grothusen C., Bley S., Selle T., et al. Combined effects of HMG-CoAreductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis. 2005 ; 182 (1). 57-69.
19. Porter KE, Turner NA Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans. 2002 ; 30 (2). 120-126.
20. Hernandez-Presa MA, Martin-Ventura JL, Ortego M., et al. Atorvastatin reduces the expression of cyclooxygenase-2 in rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002 ; 160 (1). 49-58.
21. Swanson KM, Hohl RJ Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets. 2006 ; 6 (1). 15-37.
22. Page-McCaw A., Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007 ; 8 (3). 221-233.
23. Diehm N., Di Santo S., Schaffner T., et al. Severe structural damage of the seemingly non-diseased infrarenal aortic aneurysm neck. J Vasc Surg. 2008 ; 48 (2). 425-434.
24. Defawe OD, Colige A., Lambert CA, et al. Gradient of proteolytic enzymes, their inhibitors and matrix proteins expression in a ruptured abdominal aortic aneurysm. Eur J Clin Invest. 2004 ; 34 (7). 513-514.
25. Wilson WR, Anderton M., Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneursym rupture. Circulation. 2006 ; 113 (3). 438-445.
26. Evans J., Powell JT, Schalbe E., Loftus IM, Thompson MM Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurismal aortic tissue. Eur J Vasc Endovasc Surg. 2007 ; 34 (3). 302-303.
27. Nagashima H., Aoka Y., Sakomura Y., et al. A 3-hydrozy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg. 2002 ; 36 (1). 158-163.
28. Mateos-Caceres P., Lopes-Farre AJ, Morata PC, et al. Pravastatin increases the expression of the tissue inhibitor of matrix metalloproteinase-1 and the oncogene Bax in human aortic abdominal aneurysms. Can J Physiol Pharmacol. 2008 ; 86 (7). 431-437.
29. Gottsater A., Flondell-Site D., Kolbel T., Lindblad B. Association between statin treatment and markers of inflammation, vasoconstriction, and coagulation in patients with abdominal aortic aneursysm. Vasc Endovasc Surg. 2009 ; 42 (6). 567-573.
30. Luan Z., Chase AJ, Newby AC Statins inhibit secretion of metalloproteinases-1, -2, -3 and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003 ; 23 (5). 769-775.
31. Dijke P., Arthur HM Extracellular control of TGFbeta signaling in vascular development and disease. Nat Rev Mol Cell Biol. 2007 ; 8 (11). 857-869.
32. Fukui D., Miyagawa S., Soeda J., Tanaka K., Urayama H., Kawasaki S. Overexpression of transforming growth factor β1 in smooth muscle cell of human abdominal aortic aneurysm. Eur J Endovasc Surg. 2003 ; 25 (6). 540-545.
33. Karsdal MA, Larsen L., Engsig MT, et al. Matrix metalloproteinase- dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem. 2002 ; 277 (46). 44061-44067.
34. Loeys BL, Schwarze U., Holm T., et al. Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med. 2006 ; 355 (8). 788-798.
35. Habashi JP, Judge DP, Holm TM, et al. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 ; 312 (5770). 117-121.